Page 12 - Planegg News Today

EQS-Ad-hoc: MorphoSys AG / Key word: Forecast Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces...

The biotech company Morphosys is targeting sales growth with its important drug Monjuvi for 2024 only in the best-case scenario. According to Tuesday, the SDax company aims to generate the equivalent...

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...

Investegate announcements from EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Investegate announcements from EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

German technology company Trumpf is collaborating with European space-travel start-up The Exploration Company to produce key spacecraft components using metal 3D printing. The aim is to create cost-effective, reusable spacecraft for missions to Earth's orbit and the moon.

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...

EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...